Literature DB >> 25024095

Dynamic changes in the numbers of different subsets of peripheral blood NK cells in patients with systemic lupus erythematosus following classic therapy.

Hongshuang Ma1, Ling Zhao, Zhenyu Jiang, Yanfang Jiang, Li Feng, Zhuang Ye.   

Abstract

Imbalance of natural killer (NK) cells is associated with the development of systemic lupus erythematosus (SLE). However, little is known about the dynamic changes on NK cells following therapy. This study aimed at examining the impact of classic therapies on the numbers of different subsets of NK cells in new-onset SLE patients. The numbers of different subsets of peripheral blood NK cells in 24 new-onset SLE patients before, 4 and 12 weeks post the classic therapies, and 7 healthy controls were determined by flow cytometry. The potential correlation between the numbers of NK cells and the values of clinical measures was analyzed. In comparison with that before treatment, the numbers of NK, NKG2C+, and KIR2DL3+ NK cells were significantly increased while the numbers of NKp46+ and NKG2A + NK cells significantly decreased at 4 and/or 12 weeks post the treatment only in the drug well-responding patients, but not in those poor responders (P < 0.05 for all). The numbers of NKG2C + NK cells were correlated positively with the levels of serum C3 while the numbers of KIR2DL3+ NK cells were correlated negatively with the scores of SLEDAI in these patients at 4 weeks post the treatment. The classic therapies modulated the numbers of some subsets of NK cells in drug well-responding SLE patients. The changes in the numbers of some subsets of NK cells may serve as biomarkers for evaluating the therapeutic responses of SLE.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25024095     DOI: 10.1007/s10067-014-2712-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  24 in total

Review 1.  The role of the proteasome activator PA28 in MHC class I antigen processing.

Authors:  Alice Sijts; Yuancheng Sun; Katarina Janek; Sylvie Kral; Annettte Paschen; Dirk Schadendorf; Peter-M Kloetzel
Journal:  Mol Immunol       Date:  2002-10       Impact factor: 4.407

2.  Natural killer cell signaling pathways.

Authors:  Eric Vivier; Jacques A Nunès; Frédéric Vély
Journal:  Science       Date:  2004-11-26       Impact factor: 47.728

3.  Lupus-like disease and high interferon levels corresponding to trisomy of the type I interferon cluster on chromosome 9p.

Authors:  Haoyang Zhuang; Mona Kosboth; Pui Lee; Amanda Rice; Daniel J Driscoll; Roberto Zori; Sonali Narain; Robert Lyons; Minoru Satoh; Eric Sobel; Westley H Reeves
Journal:  Arthritis Rheum       Date:  2006-05

Review 4.  The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells.

Authors:  R Testi; D D'Ambrosio; R De Maria; A Santoni
Journal:  Immunol Today       Date:  1994-10

5.  Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-γ production in patients with active disease.

Authors:  Baptiste Hervier; Vivien Beziat; Julien Haroche; Alexis Mathian; Pierre Lebon; Pascale Ghillani-Dalbin; Lucile Musset; Patrice Debré; Zahir Amoura; Vincent Vieillard
Journal:  Arthritis Rheum       Date:  2011-06

6.  Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production.

Authors:  C M Snapper; W E Paul
Journal:  Science       Date:  1987-05-22       Impact factor: 47.728

7.  Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus.

Authors:  Wen-Xian Li; Hai-Feng Pan; Jian-Li Hu; Chang-Zhong Wang; Ning Zhang; Jing Li; Xiang-Pei Li; Jian-Hua Xu; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2009-12-10       Impact factor: 2.980

Review 8.  Possible mechanisms of gender bias in SLE: a new hypothesis involving a comparison of SLE with atopy.

Authors:  I Sekigawa; T Naito; K Hira; K Mitsuishi; H Ogasawara; H Hashimoto; H Ogawa
Journal:  Lupus       Date:  2004       Impact factor: 2.911

9.  Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA.

Authors:  V Steimle; C A Siegrist; A Mottet; B Lisowska-Grospierre; B Mach
Journal:  Science       Date:  1994-07-01       Impact factor: 47.728

10.  p46, a novel natural killer cell-specific surface molecule that mediates cell activation.

Authors:  S Sivori; M Vitale; L Morelli; L Sanseverino; R Augugliaro; C Bottino; L Moretta; A Moretta
Journal:  J Exp Med       Date:  1997-10-06       Impact factor: 14.307

View more
  5 in total

Review 1.  Could Lymphocyte Profiling be Useful to Diagnose Systemic Autoimmune Diseases?

Authors:  Guillermo Carvajal Alegria; Pierre Gazeau; Sophie Hillion; Claire I Daïen; Divi Y K Cornec
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

2.  Activation status of CD56dim natural killer cells is associated with disease activity of patients with systemic lupus erythematosus.

Authors:  Manman Liu; Junli Liu; Xiaoyan Zhang; Yichuan Xiao; Gengru Jiang; Xinfang Huang
Journal:  Clin Rheumatol       Date:  2020-08-14       Impact factor: 2.980

3.  The phenotype of CD3-CD56bright and CD3-CD56dim natural killer cells in systemic lupus erythematosus patients and its relation to disease activity.

Authors:  Dwi Soelistyoningsih; Hani Susianti; Handono Kalim; Kusworini Handono
Journal:  Reumatologia       Date:  2022-09-07

4.  A Systems Biology-Based Investigation into the Pharmacological Mechanisms of Sheng-ma-bie-jia-tang Acting on Systemic Lupus Erythematosus by Multi-Level Data Integration.

Authors:  Lin Huang; Qi Lv; Fenfen Liu; Tieliu Shi; Chengping Wen
Journal:  Sci Rep       Date:  2015-11-12       Impact factor: 4.379

5.  Decreased lymphocytes and increased risk for infection are common in endogenous pediatric Cushing syndrome.

Authors:  Christina Tatsi; Rebecca Boden; Ninet Sinaii; Meg Keil; Charalampos Lyssikatos; Elena Belyavskaya; Sergio D Rosenzweig; Constantine A Stratakis; Maya B Lodish
Journal:  Pediatr Res       Date:  2017-12-06       Impact factor: 3.756

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.